SCHEMBL709015

SCHEMBL709015

COC(=O)c1ccccc1Oc1ccc(CC(CCc2ccccc2)C(=O)c2cc(OC)c(OC)c(OC)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 6/20 0.53
KMT2A Q03164 4/20 0.47
PPARA Q07869 1/20 0.43
LPAR3 Q9UBY5 1/20 0.42
MEN1 O00255 2/20 0.42
NPC1 O15118 1/20 0.42
TUBB1 Q9H4B7 1/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
G6PD P11413 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.40
FFAR1 O14842 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL968828 0.95 LPAR1 (0.58) LPAR1KMT2APPARALPAR3TUBB1
SCHEMBL709264 0.93 LPAR1 (0.61) LPAR1KMT2APPARALPAR3TUBB1
SCHEMBL708137 0.87 LPAR1 (0.65) LPAR1PPARALPAR3TUBB1LMNA
SCHEMBL708404 0.81 LPAR1 (0.74) LPAR1KMT2ATUBB1LMNAALDH1A1
SCHEMBL708862 0.80 LPAR1 (0.71) LPAR1LPAR3
SCHEMBL968829 0.79 LPAR1 (0.60) LPAR1LPAR3TUBB1LMNAHTT
SCHEMBL708144 0.78 LPAR1 (0.49) LPAR1KMT2ALPAR3MEN1TUBB1
SCHEMBL706188 0.78 LPAR1 (0.60) LPAR1KMT2ALPAR3TUBB1LMNA
SCHEMBL709759 0.77 LPAR1 (0.53) LPAR1KMT2ATUBB1LMNAALDH1A1
SCHEMBL708375 0.75 LPAR1 (0.84) LPAR1KMT2ATUBB1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553075-B1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2013-08-14 EP disclosed
EP-2565178-A1 LPA Receptor Antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2013-03-06 EP disclosed
US-8124645-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2012-02-28 US disclosed
US-7820682-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-26 US disclosed
US-20100249157-A2 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-30 US disclosed
US-20080293764-A1 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. 2008-11-27 US disclosed
US-20060148830-A1 Lpa receptor antagonist ONO PHARMACEUTICAL CO., LTD. 2006-07-06 US disclosed
EP-1553075-A1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293764-A1 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LPAR1 1/4885KMT2A 933/4885PPARA 79/4885
US-20100249157-A2 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 LPAR1 1/4885KMT2A 933/4885PPARA 79/4885
US-20060148830-A1 Lpa receptor antagonist LPAR1, LPAR2, LPAR4 LPAR1 1/4885KMT2A 933/4885PPARA 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.